Fc receptors and their interactions with immunoglobulins by Raghavan, Malini & Bjorkman, Pamela J.
               September 18, 1996 11:35 Annual Reviews RAGACHPT.DUN AR18-07
Annu. Rev. Cell Dev. Biol. 1996. 12:181–220
Copyright c© 1996 by Annual Reviews Inc. All rights reserved
Fc RECEPTORS AND THEIR
INTERACTIONS WITH
IMMUNOGLOBULINS
Malini Raghavan and Pamela J. Bjorkman
Division of Biology 156-29, and Howard Hughes Medical Institute, California
Institute of Technology, Pasadena, California 91125
KEY WORDS: immunoglobulin gene superfamily, structure, binding, transcytosis, effector func-
tions
ABSTRACT
Receptors for the Fc domain of immunoglobulins play an important role in im-
mune defense. There are two well-defined functional classes of mammalian
receptors. One class of receptors transports immunoglobulins across epithelial
tissues to their main sites of action. This class includes the neonatal Fc re-
ceptor (FcRn), which transports immunoglobulin G (IgG), and the polymeric
immunoglobulin receptor (pIgR), which transports immunoglobulin A (IgA) and
immunoglobulin M (IgM). Another class of receptors present on the surfaces of ef-
fector cells triggers various biological responses upon binding antibody-antigen
complexes. Of these, the IgG receptors (FcγR) and immunoglobulin E (IgE)
receptors (FcR) are the best characterized. The biological responses elicited
include antibody-dependent, cell-mediated cytotoxicity, phagocytosis, release of
inflammatory mediators, and regulation of lymphocyte proliferation and differ-
entiation. We summarize the current knowledge of the structures and functions of
FcRn, pIgR, and the FcγR and FcRI proteins, concentrating on the interactions
of the extracellular portions of these receptors with immunoglobulins.
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INTRODUCTION
Immunoglobulin (Ig) molecules consist of two copies of a variable Fab region
that contains the binding site for antigen, and a relatively constant Fc region
that interacts with effector molecules such as complement proteins and Fc
receptors (FcRs) (Figure 1). Receptors for the Fc domain of Ig molecules form
crucial components of immune defense by (a) facilitating specialized transport
of antibody molecules to regions of the body where they are needed, (b) forming
the crucial link between antigen binding by Igs and effector responses such as
inflammation and the regulation of antibody production, and (c) controlling the
lifetime of Ig molecules in serum.
There are five isotypes of Igs in mammals: IgA, IgD, IgE, IgG, and IgM
(Figure 1a). Particular Fc receptors are usually specific for only one or two
of the Ig isotypes. FcγR and FcRn proteins are specific for IgG, and FcR
proteins are specific for IgE. The polymeric immunoglobulin receptor (pIgR)
recognizes dimeric1 IgA and pentameric IgM. Other Fc receptors specific for
1Throughout this review, monomeric Ig refers to an Ig molecule consisting of two identical
heavy chains and two identical light chains arranged into two Fab arms and a single Fc region
(Figure 1). Thus dimeric IgA contains the four Fab arms and two Fc regions contributed from two
IgA molecules.
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−!
Figure 1 Antibody structures. (a) Schematic representations of the structures of the five Ig
isotypes. Variable and constant domains are represented by ovals. The Fc regions of the IgE and
IgM isotypes contain an extra constant domain (C2 and C2, respectively) that replaces the hinge
of the other Ig isotypes. The dimeric form of IgA and the pentameric form of IgM include an
additional 15-kDa polypeptide called the J chain. However, some antibody-producing cells secrete
a hexameric IgM that lacks the J chain (Randall et al 1992). (b) Three-dimensional structures of
IgG and the Fc fragment. Left: ribbon diagram of the structure of an intact IgG (Harris et al 1992).
The hinge region is disordered in the crystals, thus its location and the location of the disulfide
bonds linking the two heavy chains (indicated as horizontal lines) are approximate. Right: carbon-
 trace from the crystal structure of the Fc fragment (Deisenhofer 1981). The space between the
two Cγ 2 domains is filled with carbohydrate residues. The residues within the lower hinge region
that define the binding site for the FcγR receptors are disordered in this structure. Fc histidine
residues implicated in the pH-dependent interaction with FcRn (Burmeister et al 1994a, Kim et al
1994, Raghavan et al 1994, 1995a) are highlighted as sidechains with the residue name and number.
Figures were prepared from coordinates available from the PDB (1FC2 for Fc) or provided by the
authors (intact Ig coordinates obtained from A McPherson).
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Figure 2 Schematic representation of the structures of the Ig superfamily FcRs. The Ig C1-
set domains in FcRn are indicated by rectangles; V-like domains in the other FcRs are depicted
as ovals. Greek letter names are written above the subunits. The Ig-binding domains of the
FcγRs and FcRI are the  domains. Protein transmembrane regions are indicated as helices,
and the glycophosphatidyl inositol anchor of FcγRIIIB is labeled GPI. ARAMs located in the
cytoplasmic domains are indicated as diamonds, and the inhibitory motif of FcγRIIB is indi-
cated as a rectangle. FcRn and FcRI are depicted in their lying-down orientations relative
to the membrane, based on experimental data described in the text. The orientations of the
other receptors with respect to the membrane are unknown (adapted from Figure 1 in Ravetch
1994).
IgA (Maliszewski 1990), IgM (Ohno et al 1990), and IgD (Sjoberg 1980) have
been reported, but these receptors have not been extensively investigated and
are not discussed in this review. Instead, we focus on the well-characterized Fc
receptors that are members of the Ig superfamily: FcRn, pIgR, the FcγRs, and
FcRI (Figure 2), concentrating on the extracellular regions of these receptors
that are involved in ligand binding.
Ig superfamily members are defined as molecules that contain domains with
sequence similarity to the variable or constant domains of antibodies (Williams
& Barclay 1988). On the basis of sequence and structural similarities, Ig su-
perfamily member domains are divided into three sets: C1, C2, and V-like
(Williams & Barclay 1988). The C1 set includes antibody constant and topo-
logically equivalent domains. FcRn is the only FcR that is a member of the
Ig superfamily by virtue of containing constant or C1-set domains. C2 and
V-like, the other Ig superfamily domains, are common building blocks of cell
adhesion molecules (Wagner & Wyss 1994, Vaughn & Bjorkman 1996), which
are structurally similar to the other FcRs discussed in this review. The V-
like set includes domains that have a folding topology closely related to Ig
variable domains. The C2 set has a slightly different organization of -strands
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compared with the C1 and V-like sets (Figure 3). Many Ig superfamily domains
were initially classified as C2 based primarily upon the number of residues sep-
arating the cysteines that form a disulfide bond in the folded domain structure.
Indeed, the Ig-like domains in the FcγRs and in FcRI were classified as C2
and, in some cases, modeled as such (Sutton & Gould 1993, Hibbs et al 1994,
Hulett & Hogarth 1994). Recent studies by Chothia and colleagues (Harpaz
& Chothia 1994) suggest that some of the original classifications of Ig super-
family domains need to be reconsidered in light of recent crystal structures of
Ig superfamily members (for reviews, see Harpaz & Chothia 1994, Wagner
& Wyss 1994, Vaughn & Bjorkman 1996). We have therefore examined the
sequences of the FcRs, taking the new structural information into account. We
used consensus sequences for V-like and C2 domains obtained from structure-
based sequence alignments to classify the FcR domains (Vaughn & Bjorkman
1996). Our analysis indicates that the Ig-like domains within pIgR, the FcγRs,
and FcRI share features more in common with the V-like set than with the C2
set (Table 1).
Although crystal structures of the Fc binding regions of any of the receptors
except FcRn (Burmeister et al 1994a) are not available, the structures of V-
like and C2 domains in cell adhesion molecules (e.g. CD4, CD2, VCAM-1;
Ryu et al 1990, Wang et al 1990, Jones et al 1992, 1995) can be used as
approximate models for the three-dimensional structures of pIgR, the FcγRs,
and FcRI. The extracellular domains of these FcRs consist of two or more
Ig-like domains arranged in tandem, a domain organization in common with
many cell adhesion molecules including those for which three-dimensional
structures are available. As a framework for mutagenesis studies to map the
interaction site on the receptors, we present topology and ribbon diagrams
for the structures of Ig superfamily domains (Figure 3). Structural information
about the immunoglobulin ligands of the Fc receptors is more complete: crystal
structures of the IgG Fc fragment (Deisenhofer 1981) and of an intact IgG
(Harris et al 1992) are available (Figure 1b) and can be used for interpretation
of interaction site mapping studies.
Using these structural models as guides, we explore both the common fea-
tures and the differences in the way that the FcRs interact with their ligands
and discuss evidence showing that some of the Fc regions are less symmetric in
solution that one might assume from the IgG Fc crystal structure. We also refer
to the many excellent reviews covering topics not explored in detail, including
the heterogeneity of the FcγR and FcR transmembrane and intracellular re-
gions, the functional roles of different cytoplasmic domains, and FcR-mediated
signaling.
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Figure 3 Structures of the Ig superfamily domains. Topology (top) and ribbon (bottom) diagrams
are presented for each fold. -strands are identified by letters in the topology diagrams. In the
topology diagrams, the -sheet containing strands A, B, and E is dark grey and the sheet containing
strands G, F, and C is light grey. In the ribbon diagrams, the A-B-E containing -sheet is in front
of the G-F-C containing sheet. Amino acids that have equivalent positions in all structures of the
domain type are indicated by a solid circle; by the one-letter code if the identity of the amino
acid is conserved; by  for hydrophobic residues; or by the symbol  for hydrophilic residues.
-sheet hydrogen bonding is indicated by dashed lines. Regions of irregular secondary structure
are indicated by open rectangles. The antigen-binding loops in the Ig variable domain are B to C
(CDR1), C0 to C00 (CDR2), and F to G (CDR3). Loops that are structurally conserved in V-like
domains (A0 to B and E to F loops; see consensus sequence in Table 1) are thick. Ribbon diagrams
were prepared from coordinates available from the PDB (7fab for Ig constant and variable domains)
or provided by the authors (VCAM-1 coordinates from EY Jones for V-like and C2 domains)
(adapted from Figure 3 in Vaughn & Bjorkman 1996).
FcRs IN ANTIBODY TRANSPORT
Transfer of maternal IgG molecules from the mother to the fetus or infant is a
mechanism by which mammalian neonates acquire humoral immunity to anti-
gens encountered by the mother. Passive acquisition of antibody is important
to the neonate during the immediate time after birth when its immune system
is not yet fully functional. The protein responsible for the transfer of IgG is
called FcRn, for FcR neonatal (Rodewald & Kraehenbuhl 1984, Simister &
Rees 1985). Here the word neonatal derives from the initial discovery of the
receptor in the gut of suckling rats on the apical surface of intestinal epithelial
cells (Jones & Waldman 1972). Maternal IgG in ingested milk is bound by the
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receptor, transported across the gut epithelium in a process called transcytosis
(Mostov & Simister 1985), and then released into the bloodstream from the
basolateral surface (Rodewald & Kraehenbuhl 1984). There is a net pH dif-
ference between the apical (pH 6.0–6.5) and basolateral (pH 7.0–7.5) sides of
intestinal epithelial cells (Rodewald & Kraehenbuhl 1984). This pH difference
facilitates the efficient unidirectional transport of IgG, because FcRn binds IgG
at pH 6.0–6.5 but not at neutral or higher pH (Rodewald & Kraehenbuhl 1984,
Simister & Mostov 1989b, Raghavan et al 1995a).
Recent studies have shown that FcRn is also expressed in the fetal yolk sac of
rats and mice (Roberts et al 1990, Ahouse et al 1993) and in the human placenta,
where it is thought to transfer maternal IgG to the fetus (Story et al 1994,
Simister & Story 1996). In addition, FcRn is expressed on the canalicular cell
surface of adult rat hepatocytes, where it could bind IgG in bile and potentially
function to provide communication between bile and parenchymal immune cells
(Blumberg et al 1995). In this case, the proposed model for FcRn function is to
transport antibody-antigen complexes from bile to the parenchyma. Antigen-
presenting cells in parenchyma would process the antigens and present them
to T cells, which would then stimulate local B cells to secrete antigen-specific
antibodies that are transported back into the bile by unknown mechanisms
(Blumberg et al 1995). Thus FcRn appears to be used for transport of IgG in
sites other than the intestine, and in adult animals as well as neonates. Human
placental FcRn, FcRn from rat fetal yolk sac, and FcRn from rat hepatocytes
all show the same pH-dependent interaction with IgG that is observed with the
intestinal FcRn, i.e. IgG binding at pH 6.0–6.5 but not at neutral or basic pH
(Roberts et al 1990, Story et al 1994, Blumberg et al 1995). This feature of the
FcRn molecule may have evolved to facilitate IgG release from the receptor at
the slightly basic pH of blood. Because a pH gradient does not exist across
the placenta or the mammalian yolk sac, it is thought that FcRn binds IgG
intracellularly, in acidic vesicles that are targeted to the cell surface where IgG
is released upon exposure to the pH environment of blood (Roberts et al 1990,
Story et al 1994, Simister & Story 1996).
In addition to these transport functions, current evidence suggests that FcRn
is the catabolic receptor that controls the lifetime of Igs in serum. For example,
mutant Fc fragments that show impaired FcRn binding in vitro and that are
deficient for transcytosis in neonatal mice also have abnormally short serum
half lives (Kim et al 1994, Popov et al 1996). Furthermore, murine IgG1 is
degraded significantly faster in mice that are deficient in the FcRn light chain
(2-microglobulin; 2 m) (Ghetie et al 1996, Junghans & Anderson 1996, EJ
Israel, D Wilsker & NE Simister, manuscript in preparation). Because the pH
of serum is not permissive for IgG binding by FcRn, the postulated model for
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the catabolic receptor function of FcRn is that IgG is sequestered by FcRn in
acidic intracellular vesicles and subsequently rereleased into serum.
Transport of other classes of Ig in the adult mammal occurs using different
mechanisms. In order to confer specific protective functions at diverse sites,
the Ig isotypes are distributed differently throughout the body, necessitating
specific transport in some instances. The transport of IgA from the circulation
into secretions has been well studied. IgA is found in epithelial secretions such
as the lumen of the gut, the salivary and tear glands, respiratory secretions,
and breast milk, where the neutralizing capacity of IgA molecules forms the
first line of defense against entering pathogens (Underdown & Schiff 1986,
Childers et al 1989, Kerr 1990, Hanson & Brandtzaeg 1993). IgA is synthe-
sized by plasma cells beneath the basement membranes of surface epithelia.
Subsequent to synthesis, the IgA molecules must cross the epithelial cell bar-
rier to enter into secretions. Transcytosis of IgA across polarized epithelial cells
first involves the binding of IgA to pIgR proteins on the basolateral surface (re-
viewed in Kraehenbuhl & Neutra 1992, Mostov 1994). pIgR-IgA complexes
are internalized and sorted into endosomes destined for the apical surface. At
the apical surface, pIgR is cleaved and the extracellular portion of the receptor is
released into secretions as a complex with IgA. This complex, called secretory
IgA, protects against pathogens in the digestive, respiratory, and genital tracts.
The structures of FcRn and pIgR and how they interact with their respective
Ig molecules are now discussed.
FcRn
FcRn is a type I membrane glycoprotein that acts as a specific receptor for
the IgG isotype (Jones & Waldman 1972). Reported values of the equilibrium
association constant (KA) range from  2  107 M−1 for the interaction of
monomeric IgG with isolated microvilli membranes from neonatal rat intestine
(Wallace & Rees 1980) to  5  107 M−1 for the interaction between purified
soluble rat FcRn and monomeric IgG (Raghavan et al 1995b). This rather high
affinity ensures that FcRn can efficiently transport unliganded IgG, which is the
most useful form of Ig for the newborn, although transport of antigen-antibody
complexes has also been observed (Abrahamson et al 1979). Unlike the other
known FcRs, which are presumed to have monomeric extracellular Ig-binding
regions, FcRn is a heterodimer. The FcRn light chain is 2m (Simister & Rees
1985), the same light chain that is associated with class I major histocompati-
bility complex (MHC) molecules (Figure 4a). Molecular cloning of the FcRn
heavy chain revealed additional similarity to class I MHC molecules rather than
to any of the other FcRs (Simister & Mostov 1989a). The heavy chains of both
FcRn and class I MHC molecules consist of three extracellular domains, 1, 2,
and 3, followed by a transmembrane region and a short cytoplasmic sequence
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(Simister & Mostov 1989a, Bjorkman & Parham 1990) (Figure 4a). Although
the extracellular region of FcRn and class I MHC molecules exhibits low but
significant sequence similarity (22–30% identity for the 1 and 2 domains;
35–37% for the 3 domain), the transmembrane and cytoplasmic regions of
the two types of proteins show no detectable sequence similarity (Simister &
Mostov 1989a). MHC class I molecules have no reported function as Ig re-
ceptors; instead they bind and present short peptides to T cells (Townsend &
Bodmer 1989). The similarity at the primary, tertiary, and quaternary structure
levels between FcRn and class I MHC molecules suggests that they share a com-
mon ancestor, in spite of their apparently unrelated immunological functions.
THREE-DIMENSIONAL STRUCTURE OF FcRn The crystal structure of rat FcRn
confirmed that the overall fold is very similar to that of class I MHC mole-
cules, such that the 1 and 2 domains form a platform of eight anti-parallel
-strands topped by two long -helices, and the 3 and 2m domains are
-sandwich structures similar to antibody constant or C1-set domains (Figure
4a) (Burmeister et al 1994a). Although the two -helices that form the sides of
the MHC peptide-binding groove are present in FcRn, they are closer together
than their MHC counterparts, rendering the FcRn groove incapable of binding
peptides, consistent with earlier biochemical studies (Raghavan et al 1993). To
date, the FcRn counterpart of the MHC peptide-binding groove has not been
implicated in any FcRn binding function.
FcRn DIMERIZATION A dimer of FcRn heterodimers (hereafter referred to as
the FcRn dimer) mediated by contacts between the 3 and 2m domains was
observed in three different crystal forms of FcRn (Burmeister et al 1994a) (Fig-
ure 4b). Because of the 2:1 binding stoichiometry between FcRn and IgG
(Huber et al 1993), it was suggested that the FcRn dimer could represent a re-
ceptor dimer induced by IgG binding (Burmeister et al 1994a,b). In the absence
of IgG, FcRn is predominantly monomeric in solution at M concentrations
(Gastinel et al 1992); thus it was assumed that the high protein concentrations
required for crystallization could induce formation of the FcRn dimer in the ab-
sence of IgG. If the observed dimer functions in IgG binding at the cell surface,
each FcRn heterodimer would be aligned with its longest dimension roughly
parallel to the plane of the membrane (“lying down”) (Figure 5b), in contrast
to the “standing up” orientation generally assumed for class I MHC molecules
(as shown in Figure 4a).
The biological relevance of crystallographically observed dimers or oligo-
mers is a question often encountered in structural biology, because crystal
packing can induce protein multimers that are not found under physiologi-
cal conditions. Several lines of evidence, including the observation that the
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(a)
(b)
Figure 4 FcRn structure. (a) Ribbon diagrams of the structure of FcRn and a class I MHC
molecule. Both are shown in the standing-up orientation believed to be relevant for the interactions
of class I molecules with T-cell receptors. (b) Structure of the FcRn dimer observed in crystals of
FcRn alone (Burmeister et al 1994a) and crystals of a 2:1 complex between FcRn and Fc (Burmeister
et al 1994b). FcRn residues identified by site directed mutagenesis to affect the affinity of the FcRn
interaction with IgG are highlighted (His 250 and His 251, dark sidechains; residues 219–224, dark
loop; Raghavan et al 1994). The C-termini of the truncated FcRn heavy chains are labeled C. The
FcRn dimer is believed to be oriented on the cell membrane as shown in Figure 5b (a 90 rotation
about the horizontal axis from this view), so that in this orientation, the membrane is presumed to
be parallel to and below the plane of the paper. This view of the dimer corresponds to the view in
Figure 6a.
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same dimer was observed in cocrystals of a complex between rat FcRn and Fc
(Burmeister et al 1994b), indicate that the crystallographically observed FcRn
dimer is not a crystal packing artifact. The crystal structure of the FcRn-Fc
complex was solved at low resolution (4.5–6 A˚) because the crystals diffracted
poorly. However, the cocrystal structure confirmed the 2:1 FcRn-Fc binding
stoichiometry, and the high resolution structures of FcRn (Burmeister et al
1994a) and Fc (Deisenhofer 1981) were used to deduce the mode of interaction
between the two proteins. The cocrystal structure showed that the edge of the
1-2 domain platform and the N-terminal portion of 2m contact Fc at the
interface between the Cγ 2 and Cγ 3 domains. The FcRn-binding site on Fc
overlaps with the binding site for fragment B of protein A (Deisenhofer 1981),
as predicted from previous mutagenesis and inhibition studies (Kim et al 1994,
Raghavan et al 1994). Because FcRn is structurally distinct from the other
FcRs, parallels between the FcRn-IgG interaction and the interaction of Igs
with other FcRs are unlikely. Indeed, the binding site on Fc for most other
FcRs (lower hinge region and top of the Cγ 2 domain, see below; Figure 1b)
does not overlap with the binding site for FcRn. The finding that FcRn interacts
with a different portion of the Fc region than that contacted by the other FcRs
can be rationalized by the observation that at least some of the pH dependence
of the FcRn interaction with IgG arises from titration of Fc histidines at the
FcRn binding site (Figure 1b; see below).
TWO DIFFERENT 2:1 FcRn-Fc COMPLEXES The interpretation of the cocrystal
structure is complicated by the packing in the cocrystal, which creates two
distinct 2:1 FcRn-Fc complexes, only one of which incorporates the FcRn dimer.
The first 2:1 complex (the lying-down complex; Figure 5a,b) incorporates the
same FcRn dimer observed in the crystals of FcRn alone. In this complex,
the receptor dimer binds a single Fc molecule asymmetrically, with most of
the contacts involving one molecule of the dimer (Burmeister et al 1994b).
The second 2:1 FcRn-Fc complex (the standing-up complex; Figure 5c) does
not involve the receptor dimer. Instead, Fc binds symmetrically between two
FcRn molecules that are oriented with their long axes perpendicular to the
membrane. Both 2:1 complexes are built from the same 1:1 FcRn-Fc building
block (compare Figures 5a and c).
Information from the crystal structure alone could not resolve the issue of
which of these two 2:1 complexes is physiologically relevant: the standing-up
complex, the lying-down complex, or both. However, it was argued that in-
tact IgG would be sterically prohibited from binding to cell surface FcRn in
the standing-up complex because of collisions between the Fab arms and the
membrane surface (Burmeister et al 1994b). In addition, biochemical studies
established that the lying-down complex involving the FcRn dimer is required
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(a)
Figure 5 Two different 2:1 FcRn-Fc complexes observed in the crystals of FcRn bound to Fc
(Burmeister et al 1994b). FcRn residues identified by site-directed mutagenesis to affect the
affinity of the FcRn interaction with IgG are highlighted (His 250 and His 251, dark sidechains;
residues 219–224, dark loop; Raghavan et al 1994). (a) Lying-down 2:1 complex involving the
FcRn dimer. The Fc molecule interacts asymmetrically with the receptor dimer so that most of
the contacts involve one of the FcRn molecules. Contacts are predicted between the N-terminal
portion of the Cγ 2 domain and the partner FcRn molecule, in the vicinity of FcRn heavy chain
residues 219–224 (loop, shown in bold). His 250 and His 251 (highlighted) are predicted to exert
their effect on the interaction with IgG by modulating the formation of the FcRn dimer, which is
required for high-affinity binding of IgG (Raghavan et al 1995b). (b) View of the lying-down 2:1
complex rotated by 30 about the horizontal axis with respect to the orientation shown in a. The
plane of the membrane for cell surface FcRn is horizontal. No steric hindrance between intact IgG
and the membrane is expected in this orientation, as the two Fab arms of IgG could project out of
the plane of the paper and into the plane of the paper. (c) The standing-up 2:1 complex oriented
so that the plane of the membrane for cell surface FcRn is horizontal. Steric hindrance between
the Fab arms of intact IgG and the membrane is predicted for this complex. In addition, neither
of the regions indicated by site-directed mutagenesis to affect IgG binding affinity (histidines 250
and 250, highlighted; loop, comprising residues 219–224, bold) (Raghavan et al 1994) are at the
Fc interface or any other protein-protein interface.
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(b)
(c)
Figure 5 (Continued)
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for high-affinity binding of IgG. The mutation of two histidine residues located
at the FcRn dimer interface (Figures 4b, 5a,b) reduced the binding affinity for
IgG (Raghavan et al 1994). These histidines are distant from the IgG-binding
site and cannot directly contact Fc; thus their effect on IgG affinity is hypoth-
esized to be an indirect result of modulating the formation of the FcRn dimer,
which is predicted to have a higher affinity for IgG than an FcRn monomer. The
prediction that the FcRn dimer has a higher IgG-binding affinity than an FcRn
monomer was directly tested in biosensor studies using oriented coupling of
FcRn molecules. These studies showed high-affinity IgG binding when FcRn
was immobilized on a biosensor chip in an orientation facilitating dimerization,
but an affinity reduction of over 100-fold when FcRn dimer formation was hin-
dered (Raghavan et al 1995b). Examination of the predicted contacts between
Fc and the two FcRn molecules in the lying-down 2:1 complex lends support to
the idea that dimerization of FcRn results in an increased affinity for IgG, in that
contacts between Fc and the second FcRn molecule are predicted in the regions
near residues 219 and 245 of the 3 domain of FcRn and residues 272 and 285
in the Cγ 2 domain of Fc (Burmeister et al 1994b) (Figure 5a). Site-directed
mutagenesis confirmed that alteration of residues in the region of residue 219
of the FcRn heavy chain affected IgG binding affinity (Raghavan et al 1994)
(Figure 5a,b).
Thus the available evidence suggests that FcRn dimerization is indeed in-
volved in IgG binding and that the lying-down 2:1 complex is physiologically
relevant for the binding of intact IgG by FcRn molecules at the cell surface.
The crystallographic and biochemical results raise the possibility that FcRn
functions like many other cell surface receptors in which ligand-induced dimer-
ization is required for downstream signal transduction (Heldin 1995) which, in
this case, would initiate the endocytosis of IgG-FcRn complexes. However,
the lying-down 2:1 FcRn-Fc complex does not take advantage of the twofold
symmetry of the Fc homodimer, because the FcRn binding site on one of the
Fc polypeptide chains is not used (Figure 5a,b). Both binding sites are utilized
in the cocrystals because the standing-up and lying-down complexes coexist to
form an oligomeric ribbon with an overall stoichiometry of two receptors per
Fc (Figure 6). If both complexes exist in the cocrystals, could both complexes
form in vivo?
We recently proposed a model in which IgG-induced dimerization of FcRn
followed by the creation of networks that include both the standing-up and lying-
down 2:1 FcRn-IgG complexes (Figure 6) signals the initiation of transcytosis in
vivo (Burmeister et al 1994b). This model requires that networks of FcRn-IgG
complexes are formed between parallel adjacent membranes separated by170
A˚ (Figure 6b). The requirement for closely spaced parallel adjacent membranes
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(a)
(b)
Figure 6 Network of FcRn-Fc complexes observed in the cocrystals (Burmeister et al 1994) as
a model for the formation of higher order oligomers upon binding of IgG to cell surface FcRn.
FcRn is grey and Fc is black. (a) Top view illustrating the simultaneous formation of lying-down
and standing-up FcRn-Fc complexes. If this network is formed under physiological conditions,
each FcRn dimer would be associated with a membrane parallel to the plane of the paper: the
left-most dimer is associated with a membrane below the plane of the paper, the central dimer
with a membrane above the plane of the paper, and the right-most dimer is again associated with a
membrane below the plane of the paper. (b) Side view, rotated by 90 about the horizontal axis from
the view in a. The FcRn dimers are seen looking down their long axes (vertical in a). Existence
of this network under physiological conditions would require two parallel membranes separated
by 160 to 170 A˚ (Burmeister et al 1994b). Adjacent microvilli membranes in the brush borders
of neonatal rat epithelial cells can be separated by as little as 200 A˚ (Rodewald 1973), consistent
with the possibility that networks of 2:1 FcRn-IgG complexes form between adjacent microvilli
membranes.
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is fulfilled in the microvilli of the brush border epithelial cells (Rodewald 1973)
where FcRn is expressed and functions, but the bridging of adjacent membranes
by IgG bound to FcRn dimers remains to be demonstrated. However, recent
evidence suggests that both Fc binding sites are required for FcRn function
in vivo, in that a hybrid Fc heterodimer containing one functional and one
disrupted FcRn binding site is not transcytosed efficiently into the bloodstream
of newborn mice (Kim et al 1994). The same hybrid Fc heterodimer was found
to bind with normal affinity to mouse FcRn immobilized on a biosensor chip
(Popov et al 1996). This latter observation was interpreted as support for a 1:1
binding stoichiometry between mouse FcRn and IgG (Popov et al 1996) but
is also consistent with a 2:1 stoichiometry involving the FcRn dimer and the
utilization of only one FcRn binding site on the Fc molecule (Figure 5a,b). In
combination with the previously described results, these experiments suggest
that the lying down FcRn-Fc 2:1 complex is necessary, but not sufficient, for
transcytosis of IgG, and that both 2:1 complexes are relevant for FcRn function
in vivo.
We have argued that the bridging of FcRn dimers on two adjacent membranes
by IgG molecules is a prerequisite for transcytosis. However, when we pre-
pare FcRn-Fc complexes atM concentrations in solution, size exclusion chro-
matography suggests that the predominant species is a 2:1 receptor-Fc complex,
rather than a higher-order multimer (AH Huber, L Sanchez & PJ Bjorkman,
unpublished data). It is possible that higher-order multimers appear only under
special circumstances of high local protein concentrations, i.e. in the cocrystal
(mM concentration) or when FcRn dimers are constrained to adjacent mem-
branes separated by the optimal distance for bridging by IgGs. One explanation
for this involves the idea that the Fc region of IgG is asymmetric, such that only
one of the FcRn-binding sites is in an optimal conformation for receptor bind-
ing. As a precedent for this idea, the Fc region of IgE is strongly bent both
in solution and when bound to its receptor (reviewed in Baird et al 1993) and
thus only one of the FcRI binding sites on the IgE Fc appears to be accessible
(discussed in FcRI section; reviewed by Sutton & Gould 1993). There is evi-
dence that IgG is also bent in solution (Baird et al 1993), and the FcRn binding
sites might therefore be in slightly different conformations on both polypeptide
chains. The low resolution of the cocrystal structure and the disorder of the
N-terminal portion of the Cγ 2 Fc domain (Burmeister et al 1994b) prevent the
use of this crystal structure to determine whether Fc is bent when bound to
FcRn. However, it is clear that in the crystals both FcRn-binding sites on Fc
interact with an FcRn molecule, so one must assume that any Fc bending that
occurs does not completely occlude either of the FcRn binding sites under the
conditions of high protein concentration in the cocrystal.
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pH DEPENDENCE OF THE FcRn-Fc INTERACTION To function as an efficient uni-
directional transporter of IgG molecules, FcRn must bind IgG with high affinity
prior to and during transcytosis and release intact IgG molecules at the end point
of transport. As mentioned above, release of IgG from FcRn occurs rapidly
upon exposure to environments of neutral pH such as the blood. Indeed, the
affinity of FcRn for IgG is relatively stable between pH 5 and 6, then drops
steeply by over two orders of magnitude as the pH is raised from 6.0 to 7.0
(Raghavan et al 1995a). The dramatic pH dependence of FcRn binding to IgG
is unusual for protein-protein interactions. Histidine residues are likely candi-
dates for effecting such pH-dependent affinity changes because the imidazole
side chain usually deprotonates over the pH range of 6.0 to 7.0. Mutagenesis
(Kim et al 1994), inhibition studies (Raghavan et al 1994), and the FcRn-Fc
cocrystal structure (Burmeister et al 1994b) implicate conserved histidines at
the interface of the Cγ 2 and Cγ 3 domains. A biosensor pH dependence assay
was used to analyze the role of histidine residues in Fc and FcRn in the affinity
transition (Raghavan et al 1995a). These studies suggest that the lying-down
2:1 FcRn-IgG complex is destabilized at neutral or basic pH values by titra-
tion of IgG histidine residues located at the IgG-FcRn interface (IgG His 310
and His 433; Figure 1b) as well as FcRn histidines located at the FcRn-FcRn
dimer interface (FcRn His 250 and His 251; Figures 4b, 5a,b) (Raghavan et al
1995a). Thus an intricate molecular network of interactions has evolved to fa-
cilitate the binding and release of IgG by FcRn, a situation quite different from
pIgR-mediated transport of IgA, where a proteolytic cleavage step is utilized
to release IgA into secretions (see below). The advantage conferred upon the
FcRn transporter system is that the same receptor molecule can be used for
multiple rounds of transport.
pIgR
pIgR is so called because of its ability to transport polymeric Ig molecules:
IgA and IgM (Brandtzaeg 1981). Serum IgA is produced in the bone marrow
in a primarily monomeric form, whereas the IgA in secretions, the product of
local synthesis at mucosal surfaces, is associated with a protein called the J
chain and is primarily dimeric (Kerr 1990) (Figure 1a). The J chain is not
required for IgA dimerization, but it appears to have a role in maintaining
dimer stability (Hendrickson et al 1995). IgM is found in both pentameric and
hexameric forms; only the pentameric form includes the J chain (Randall et al
1992). pIgR transports the dimeric form of IgA and the pentameric form of IgM
(Brandtzaeg 1981). It is not known if IgM hexamers are transported by pIgR.
pIgR TRANSPORT After synthesis, pIgR transits from the endoplasmic reticu-
lum to the Golgi and then to the trans-Golgi network, where the receptor is
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specifically targeted to the basolateral membrane of epithelial cells (reviewed
in Mostov 1994). The basolateral targeting signal is contained in a 17-amino
acid sequence of the cytoplasmic domain immediately C-terminal to the pre-
dicted transmembrane region (Casanova et al 1991). IgA binding occurs at the
basolateral surface. Binding of IgA to pIgR stimulates transcytosis to the apical
side of the cell, but some transcytosis of unliganded pIgR occurs constitutively
(Song et al 1994). The direction of pIgR transcytosis, from the basolateral to
apical side of the cell, is opposite to the direction of FcRn transcytosis, consis-
tent with the opposite functions of the two receptors: pIgR to deposit Ig into
secretions such as milk and FcRn to retrieve Ig from ingested milk.
In the transcytotic pathway, pIgR and pIgR-Ig complexes are first internal-
ized into endosomes. Targeting of endosomes containing pIgR and pIgR-Ig
complexes to the apical surface is thought to involve the same sorting signals
and proteins required for basolateral targeting from the trans-Golgi network
(Aroeti & Mostov 1994). At the apical surface, the extracellular portion of
pIgR is cleaved at a site near the transmembrane sequence, and the extracellu-
lar portion of pIgR (called secretory component; SC) is released either alone
or as a complex with IgA. The protease(s) involved in cleavage have not been
characterized, but multiple C-terminal residues have been identified on SC,
implying cleavage by multi- or nonspecific protease(s) (Eiffert et al 1984). Be-
cause pIgR is cleaved during the transcytosis process, it is used for only a single
round of transport.
The cleavage of pIgR and formation of the SC-IgA complex confer enhanced
resistance to proteolysis in the protease-rich mucosal environment (Underdown
& Dorrington 1974). Once SC-IgA complexes are released into secretions,
target microorganisms are efficiently cross-linked because dimeric IgA contains
a total of four antigen-binding sites. The resulting large particles show retarded
movement to the mucosal surface and can therefore be trapped in the mucus and
cleared (Underdown & Schiff 1986, Kraehenbuhl & Neutra 1992). SC-IgA may
also function by binding to microorganisms so as to prevent their interactions
with the epithelia. In addition, SC-IgA can participate in direct killing of
pathogens by facilitating the interaction of an antibody-bound microorganism
with Fc receptor-bearing macrophages and neutrophils in the mucosal surfaces
(Underdown & Schiff 1986).
pIgR STRUCTURE pIgR is a glycosylated type I membrane protein containing
an extracellular domain of about 629 amino acids, a single transmembrane
region, and a cytoplasmic domain of 103 amino acids, with a total molecular
weight of 100,000–105,000 (Mostov et al 1984). The extracellular portion
is organized into five homologous domains that most closely resemble V-like
domain members of the Ig superfamily (Mostov et al 1984) (Figure 2). The
A
nn
u.
 R
ev
. C
el
l. 
D
ev
. B
io
l. 
19
96
.1
2:
18
1-
22
0.
 D
ow
nl
oa
de
d 
fro
m
 ar
jou
rna
ls.
an
nu
alr
ev
iew
s.o
rg
by
 C
A
LI
FO
RN
IA
 IN
ST
IT
U
TE
 O
F 
TE
CH
N
O
LO
G
Y
 o
n 
09
/0
8/
05
. F
or
 p
er
so
na
l u
se
 o
nl
y.
         September 18, 1996 11:35 Annual Reviews RAGACHPT.DUN AR18-07
Fc RECEPTORS 201
structure of pIgR is therefore very different from that of FcRn, the previously
discussed FcR involved in Ig transport. As is the case for most FcRs, the
extracellular portion of pIgR consists of multiple Ig-like domains arranged in
tandem (Figure 2).
THE pIgR-Ig INTERACTION The derived affinity of interaction between SC and
polymeric IgM is high: reported values for the KA are  6  108 M−1 to
2  109 M−1 for the human SC-IgM interaction (Goto & Aki 1984). The
binding of IgA to pIgR involves noncovalent interactions as well as covalent
interactions thought to stabilize the complex (Mestecky & McGhee 1987); thus
SC remains complexed to IgA in the mucosal environment to provide protection
from proteolysis. By contrast to human SC-Ig complexes, some rabbit SC-Ig
complexes are noncovalent (Knight et al 1975). The reported KA values for the
rabbit SC-IgA interaction are  1  108 M−1 (Ku¨hn & Kraehenbuhl 1979),
indicating tight binding even in the absence of covalent interactions.
Several pieces of evidence suggest that the N-terminal (membrane distal) Ig
domain of pIgR is the primary determinant of the noncovalent interaction of
pIgR with IgA (Frutiger et al 1986, Bakos et al 1991, Coyne et al 1994). It was
originally demonstrated that a proteolytic fragment containing pIgR domain 1
could bind to IgA (Frutiger et al 1986). Site-directed mutagenesis of sequences
in the regions predicted to encompass the B to C, C0 to C00, and F to G loops of
domain 1 resulted in a significant reduction or nearly complete abrogation of
IgA binding, suggesting that the binding site for IgA includes the counterparts
of the antigen-binding loops in Ig variable domains (Coyne et al 1994) (Figure
3). In addition, the human SC-pIgR interaction involves a covalent interaction
between Cys 311 of the C2 domain of one IgA heavy chain and Cys 467 of
domain 5 of SC (Fallgreen-Gebauer et al 1993). Thus the binding interactions
of pIgR involve the tip of domain 1, as well as domain 5, which are predicted to
be separated by 150 to 170 A˚ if the five Ig-like domains in pIgR are aligned in
a strictly end-to-end fashion with no significant kinks between domains (based
on measurements of the Ig-like domains in crystal structures of CD4, CD2, and
VCAM-1; Ryu et al 1990, Wang et al 1990, Jones et al 1992, 1995, Brady et al
1993). By contrast, the Fc region of IgA would be no more than 60 A˚ in length.
This information suggests either that pIgR contacts both Fc regions in the IgA
dimer or that it is significantly bent, or a combination of both possibilities.
There are little available data concerning the location of the sites on the
IgA dimer or the IgM pentamer that determine their interactions with pIgR.
Inhibition studies using monoclonal antibodies have suggested that regions of
the C2 and C3 domains of IgA are involved in interactions with SC (Geneste
et al 1986), although the contribution of residues 381–411 of the C3 domain
was ruled out in studies of pIgR binding by an IgA molecule lacking these
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residues (Switzer et al 1992). It has been suggested that the pIgR binding
site on IgA and IgM involves the J chain (Brandtzaeg & Pyrdz 1984), but
the involvement of the J chain in pIgR binding is controversial (see Mestecky
& McGhee 1987). Recent work using transport assays with pIgR-transfected
Madin-Darby canine kidney (MDCK) cells showed impaired transport of IgA
isolated from mice lacking the J chain (Hendrickson et al 1995), but this result
does not distinguish between the possibility that pIgR directly contacts the J
chain or that the IgA structure is altered in the absence of the J chain. The
reported 1:1 stoichiometry of the SC-IgA interaction [one molecule of SC
associated with one (IgA)2-J chain complex] (Goto & Aki 1984, Mestecky &
McGhee 1987) could be interpreted as consistent with the idea that SC interacts
with the J chain. However, more structural and biochemical information will be
required to understand the complete molecular details of the pIgR-Ig complexes.
FcRs IN ANTIBODY-MEDIATED EFFECTOR
RESPONSES
FcRs for IgG and IgE are present on the surfaces of several accessory cells of the
immune system. These receptors, designated FcγRs for those that bind IgG,
and FcRs for those that bind IgE, interact with antibody-antigen complexes
to activate various biological responses. Here we review the functions of the
FcγR and FcR proteins and discuss the various forms of each type of receptor
and how they are thought to interact with their Ig ligands.
Effector responses mediated by FcγRs include phagocytosis, endocytosis,
antibody-dependent cell-mediated cytotoxicity (ADCC), the release of medi-
ators of inflammation, and the regulation of B cell activation and antibody
production (reviewed in Unkeless et al 1988, van de Winkel & Anderson
1991). Phagocytosis involves the engulfing of microbial particles, internal-
ization into acidified cytoplasmic vesicles called phagosomes, and fusion of
phagosomes with lysosomes, upon which lysosomal enzymes destroy the mi-
crobe (Silverstein et al 1989, CL Anderson et al 1990). The process of phago-
cytosis is distinguished from endocytosis by the size of the particle that is
internalized and degraded, with phagocytosis referring to ingestion of parti-
cles of 1 M or greater in diameter (Silverstein et al 1977). FcγRs mediate
the internalization of smaller IgG-antigen complexes via endocytosis, which
enhances the efficiency of antigen presentation by class II MHC molecules
(Amigorena et al 1992b). In addition, FcγRs present on cells such as natural
killer cells mediate interactions with antibody-coated target cells, resulting in
the destruction of target cells by ADCC (reviewed in Unkeless et al 1988, van
de Winkel & Anderson 1991).
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On mast cells, the receptor for IgE, FcRI, binds monomeric IgE with high
affinity. Upon cross-linking of the IgE by interaction with multivalent antigens,
inflammatory responses are activated. These responses include the release of
histamines, serotonin, and leukotrienes, resulting in fluid accumulation and the
influx of cells and proteins to contain infection (Beaven & Metzger 1993, Sutton
& Gould 1993, Ravetch 1994).
Molecular cloning of the genes encoding the FcγR and FcR proteins re-
vealed the existence of three major classes of FcγRs (FcγRI, FcγRII, FcγRIII)
and two classes of FcRs (FcRI and FcRII). The Ig-binding portions of
FcγRI, FcγRII, FcγRIII, and FcRI (the  chains) are members of the Ig gene
superfamily, all type I transmembrane proteins containing an extracellular re-
gion with two or more Ig-like domains and a polypeptide or lipid anchor in
the membrane (Figure 2) (reviewed in Ravetch & Kinet 1991, Burton & Woof
1992, Hulett & Hogarth 1994). The extracellular regions of the FcγR and
FcRI receptors show significant sequence similarity to each other: 70–98%
sequence identity within the FcγRs and about 40% sequence identity between
the FcγRs and FcRI (reviewed in Ravetch & Kinet 1991, Ravetch 1994).
FcRII, a type II integral membrane protein containing a C-terminal extracel-
lular region that includes a C-type lectin domain (Kikutani et al 1986), is not
a member of the Ig superfamily and is not included in this discussion of the Ig
superfamily FcRs.
The  subunits of many of the Ig superfamily FcRs are found in multiple
forms (Ravetch et al 1986, Stuart et al 1989, Qiu et al 1990, Ernst et al 1992;
reviewed in Ravetch & Kinet 1991, Fridman et al 1992, Hulett & Hogarth
1994). In the mouse, single genes encode each of the three classes of FcγR,
whereas in humans, three FcγRI, three FcγRII, and two FcγRIII genes have
been identified (reviewed in Ravetch 1994, Hulett & Hogarth 1994). Figure 2
shows the isoforms of the FcγRs discussed in this review. Differences in the
cytoplasmic domains of the two FcγRII isoforms result in important functional
differences (see below). The two FcγRIII isoforms differ in their membrane
anchorage; one isoform is anchored to the membrane with a polypeptide chain,
and the second isoform is anchored to the cell surface with a glycophosphatidyl
inositol (GPI) linkage (Ravetch & Perussia 1989) (Figure 2). In addition to
the membrane-bound form of FcRs, soluble versions generated by alternative
splicing of the transmembrane exon or by proteolysis of membrane-bound forms
are found in the circulation (Fridman 1991, Galon et al 1995). The soluble forms
of FcRs may play an immunoregulatory role by interfering with the functions
of their membrane bound counterparts (Fridman 1991, Galon et al 1995).
The ligand-binding domains of some FcRs are associated in the membrane
with other proteins that are required for receptor assembly and signaling. The
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 chains of FcRI and FcγRI associate with an integral membrane protein
called the γ chain (Perez-Montfort et al 1983, Ra et al 1989, Ernst et al 1993,
Scholl & Geha 1993). The γ chain is homologous to the  chain, a protein
originally identified as essential for the assembly and signaling of the T-cell
receptor-CD3 complex (Weissman et al 1989). Both γ and  chains associate
with FcγRIII (Hibbs et al 1989, Lanier et al 1989). The cytoplasmic domains of
γ and  chains share a common tyrosine-containing sequence motif called the
antigen receptor activation motif (ARAM) (Reth 1989, Weiss & Littman 1994),
ITAM (Cambier 1995), TAM (Samelson & Klausner 1992), or the ARH1 motif
(Cambier 1992). In FcR signaling, as observed for signaling via the T and B
cell receptors (Weiss & Littman 1994), the ARAM motifs associate with Src
family protein tyrosine kinases that are activated upon receptor cross-linking to
initiate a cascade of signal transduction events (Keegan & Paul 1992, Lin et al
1994).
We now review current knowledge about the structures of FcγRI, FcγRII,
FcγRIII, and FcRI; their affinities and specificities for Ig; and binding domains
interactions, and we discuss recent insights into the biological responses elicited
by each receptor.
FcγRI
FcγRI is expressed on the surfaces of neutrophils, monocytes, granulocytes
and macrophages (van de Winkel & Anderson 1991, Hulett & Hogarth 1994).
Three human FcγRI genes have been identified, one encoding a transmem-
brane receptor with three Ig-like domains (Figure 2), and two encoding soluble
receptors with three Ig-like domains. Alternative splicing of one of the solu-
ble receptor genes results in an mRNA for a transmembrane receptor with two
Ig-like domains (Ernst et al 1992). Of these isoforms, expression of only the
transmembrane receptor with three Ig-like domains (FcγRIA) has been demon-
strated. This receptor binds monomeric IgG with high affinity with reported
KA values ranging from 2 109 M−1 (for the binding of human IgG1 to human
monocyte-like U937 cells expressing endogenous FcγRI; Shopes et al 1990)
to 5  109 M−1 (for the binding of human IgG1 to COS cells transfected with
human FcγRI; Allen & Seed 1989). Human IgG3 binds with an affinity com-
parable to human IgG1, but human IgG4 and human IgG2 bind more weakly
(Allen & Seed 1989). The unique role of FcγRI compared with the low-affinity
receptors FcγRII and FcγRIII may lie in the capability of FcγRI to trigger ef-
fector responses at low IgG concentrations, which are typical of early immune
responses in vivo (Shen et al 1987).
The  chains of human and murine FcγRI consist of three extracellular Ig-
like domains that show features most closely resembling the V-like set (Figure
2, Table 1), a transmembrane region, and a cytoplasmic domain (Allen & Seed
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1989, Sears et al 1990, Ernst et al 1992). The  chain associates on cell surfaces
with a γ homodimer (Ernst et al 1993) (Figure 2). Although transfection
studies in COS cells show that the γ chain is not required for stable cell surface
expression of FcγRI (Ernst et al 1993), macrophages derived from γ chain
knockout mice do not bind murine IgG2a, which suggests that γ is required for
FcγRI function in vivo (Takai et al 1994).
FcγRI FUNCTIONS FcγRI mediates ADCC, endocytosis, and phagocytosis in
vitro (Shen et al 1987, CL Anderson et al 1990, Davis et al 1995). Despite
the ability of FcγRI to bind monomeric IgG with high affinity, signals for en-
docytosis/degradation and phagocytosis are transduced by FcγRI only upon
receptor cross-linking (Davis et al 1995). Although association of FcγRI
with monomeric IgG results in internalization, the receptor-IgG complexes are
rapidly recycled to the cell surface (Harrison et al 1994). Cross-linking of recep-
tors at the cell surface also promotes internalization, but instead of being recy-
cled, the receptor-ligand complexes are retained in intracellular compartments
and subsequently degraded (Mellman & Plutner 1984, Harrison et al 1994).
Internalization and degradation of cross-linked FcγRI-IgG-antigen complexes
could lead to the enhanced presentation of peptide antigens on class II MHC
molecules, as described for FcγRIII-immune complex interactions (Amigorena
et al 1992b). However, because antigens associated with monomeric IgG bound
to FcγRI are not degraded, FcγRI may not have a role in the enhancement of
presentation of antigens with single epitopes.
FcγRI-IgG INTERACTION FcγRI contains an extra Ig-like domain in its extra-
cellular portion compared with the lower-affinity receptors FcγRII and FcγRIII
(Figure 2). The first two extracellular domains of FcγRI share greater sequence
similarity with the two extracellular domains of FcγRII and FcγRIII than does
the third domain, which suggests that the third domain is responsible for some
of the interactions that confer high-affinity binding upon FcγRI (Allen & Seed
1989). Studies with mutant and chimeric FcRs demonstrate that removal of the
third domain of murine FcγRI abrogates high-affinity binding to monomeric
IgG, although domains 1 and 2 on their own retain a weak affinity for IgG.
Linking FcγRI domain 3 to domains 1 and 2 of FcγRII does not confer high-
affinity binding of monomeric IgG to FcγRII (Hulett et al 1991). Thus regions
of FcγRI in addition to domain 3 are required for high-affinity binding of
monomeric IgG (Hulett & Hogarth 1994).
The interaction sites on IgG for human FcγRI have been mapped in several
studies that measured the binding of IgG and chimeric Igs to FcγRI expressed
on U937 cells. Domain swap experiments involving chimeric IgGs constructed
from different subtypes and chimeric IgE-IgG molecules identified the Cγ 2
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domain of IgG as an interaction site for FcγRI (Shopes et al 1990, Canfield
& Morrison 1991). Mutagenesis studies showed that residues 234–237 of
the lower hinge region as well as residue 331 in the Cγ 2 domain of IgG are
important (Duncan et al 1988, Canfield & Morrison 1991, Lund et al 1991)
(Figure 1b). The binding sites for the closely related low affinity FcγRs (FcγRII
and FcγRIII) have been mapped to a similar region of IgG, and FcRI appears
to bind to an analogous place on the IgE Fc region (Hulett & Hogarth 1994; see
below). Asn 297 of the Cγ 2 domain is a conserved N-linked glycosylation site
in IgG molecules. Alteration of the carbohydrate structure reduced the binding
affinity of human FcγRI for IgG1 by four- to sixfold (Wright & Morrison 1994),
implying involvement of carbohydrate in the receptor binding, either by direct
interaction with the receptor, or by indirectly affecting the Fc conformation.
The Ig-binding domains of the FcγRs and FcRI proteins are generally as-
sumed to be monomeric, based on analogy to similar Ig superfamily structures
including CD4, CD2, and VCAM-1 (Ryu et al 1990, Wang et al 1990, Jones et al
1992, 1995). Indeed, FcγRI has been shown to bind only a single IgG molecule
(O’Grady et al 1986), consistent with, but not conclusively demonstrating, the
supposition that it is a monomer. However, all Ig Fc regions are dimers com-
posed of two identical polypeptide chains (Figure 1b), each of which could
theoretically interact with a single FcR to produce a 2:1 receptor-Ig stoichiom-
etry. However, only one of two binding sites on IgG is utilized in the interaction
with FcγRI (Koolwijk et al 1989), implying a 1:1 receptor-IgG stoichiometry.
This issue is explored in more detail in the sections on FcγRIII and FcRI when
other measurements of receptor-Ig stoichiometry are discussed.
FcγRII
FcγRII is very widely distributed among cells of the immune system (van de
Winkel & Anderson 1991, Hulett & Hogarth 1994). Unlike FcγRI, which binds
unaggregated IgG with high affinity, FcγRII binds monomeric IgG with low to
undetectable affinity (estimated KA<1107 M−1 for human FcγRII binding to
IgG; Hulett & Hogarth 1994). Under physiological conditions, the low affinity
of FcγRII for monomeric IgG ensures that this receptor (and FcγRIII) interact
only with IgG that has been aggregated by binding to multivalent antigens.
Although the γ chain is not required for FcγRII expression, γ has been
observed in association with the  chain of human FcγRII (Masuda & Roos
1993). In mice, γ chain knockouts are impaired for the FcγRII-mediated
phagocytic function of macrophages, although the expression levels of FcγRII
are normal (Takai et al 1994). These results suggest that γ may be required to
elicit biological responses associated with murine FcγRII (Takai et al 1994),
consistent with the absence of an ARAM motif in murine FcγRII.
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FcγRII ISOFORMS AND FUNCTION The  chains of human and murine FcγRII
contain two extracellular Ig-like domains connected to a transmembrane and
cytoplasmic region (Figure 2). The sequences of the two domains show char-
acteristics of Ig V-like domains (Table 1), although they have been previously
classified and modeled as C2 domains (Hulett & Hogarth 1994). Three human
genes and one murine FcγRII gene have been identified (Ravetch et al 1986,
Brooks et al 1989, Stuart et al 1989) encoding multiple transcripts that differ
primarily in their cytoplasmic tails (Ravetch & Kinet 1991).
The FcγRII proteins exemplify how distinct biological responses can be
elicited by differences in the cytoplasmic domains of receptors that have com-
mon extracellular ligand-binding domains (Ravetch 1994). The murine FcγRII
gene has two transcripts, 1 and 2 (or b1 and b2). 1 contains a 46-amino
acid insertion in the cytoplasmic region (Ravetch et al 1986) that prevents
efficient FcγRII1-mediated endocytosis (Miettinen et al 1989). B lympho-
cytes preferentially express the 1 isoform of FcγRII and are thus deficient in
FcγRII-mediated endocytosis and enhancement of peptide antigen presenta-
tion by class II MHC molecules (Amigorena et al 1992a). This is thought to be
important in order to limit B cell stimulation by T cells to antigens for which
the B cell is specific; i.e. those internalized because of binding to the B cell
receptor, rather than those internalized via IgG binding to FcγRII (Amigorena
et al 1992a).
Both in vitro and in vivo studies have shown that FcγRII acts as a negative
regulator of immune complex–triggered activation (Muta et al 1994, Daeron
1995, Takai et al 1996). On B lymphocytes, cross-linking of FcγRII1 and
membrane bound Ig by complexes of antigen and soluble antibody modulates
B cell activation (Amigorena et al 1992a, Muta et al 1994), providing a feed-
back mechanism for regulation of B cell stimulation at high soluble antibody
concentrations. In vitro reconstitution studies suggest that FcγRII can also
inhibit FcRI-triggered activation of mast cells (Daeron 1995). Recent stud-
ies of FcγRII-deficient mice confirmed that FcγRII functions in vivo as an
inhibitory receptor for both B cells and mast cells (Takai et al 1996). FcγRII-
deficient mice display elevated Ig levels and demonstrate decreased thresholds
for mast cell activation induced by FcγRIII (Takai et al 1996). The FcγRII
isoforms that mediate these inhibitory functions do not contain ARAM motifs,
and their cytoplasmic regions are indicated as “inhibit” in Figure 2. Both the
murine 1 and 2 isoforms inhibit B-lymphocyte activation (Amigorena et al
1992a), as does the human homologue FcγRIIB (Ravetch 1994) [this protein
has also been referred to as FcγRIIb (Brooks et al 1989) or FcγRIIC (Stuart
et al 1989, Ravetch 1994)]. Other human FcγRII proteins contain the ARAM
motifs in their cytoplasmic domains, which allows these receptors to mediate
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conventional cellular activation upon receptor cross-linking (indicated as ARAM
in Figure 2).
FcγRII-IgG INTERACTION Unlike pIgR, which mainly uses its N-terminal Ig-
like domain for interactions with IgA, most of the direct binding interactions
between FcγRII and IgG involve the second domain of this receptor (Hulett &
Hogarth 1994). Residues 154–161, 109–116, and 130–135 of the second Ig-like
domain have been implicated in ligand binding (Hulett et al 1995) (underlined
in Table 1). When these regions were modeled onto the structure of a Ig
superfamily C2 domain (Hulett et al 1995), they corresponded to the F to G,
B to C, and C0 to E loops (Figure 3). All three loops are predicted to be on
the upper portion of the second domain, at the interface with the bottom of the
first domain (Hulett et al 1995). The IgG binding site is therefore thought to
involve the domain 1-domain 2 interface, with the first domain being required
for stabilization of the regions of the second domain that interact with IgG
(Hulett et al 1995).
The binding site on IgG for human FcγRII involves the same region of the
IgG molecule as does the binding site for FcγRI; mutagenesis results implicate
residues 234 to 237 of the lower hinge region adjacent to the Cγ 2 domains
(Lund et al 1991). Removal of the carbohydrate residues between the two Cγ 2
domains also affects the ability of FcγRII to bind IgG (Walker et al 1989). Taken
together with results mapping the FcRI-IgE interface to analogous regions on
both the receptor and Ig ligand, the idea that the related IgG and IgE FcRs
employ similar modes of interaction seems reasonable (Hulett & Hogarth 1994;
see below).
FcγRIII
FcγRIII is expressed on macrophages, neutrophils, and mast cells and is the
only FcR found on natural killer cells (van de Winkel & Anderson 1991, Hulett
& Hogarth 1994). Like FcγRII, FcγRIII is classified as a low-affinity receptor
for IgG. The Fc fragment of IgG binds human FcγRIII with a KA value of 1.7
 105 M−1 (Ghirlando et al 1995).
FcγRIII ISOFORMS AND FUNCTION Two human FcγRIII  chain genes have
been identified, FcγRIIIA and FcγRIIIB, both encoding proteins containing
an extracellular portion of 180 amino acids with two Ig-like domains (Ravetch
& Perussia 1989). The Ig-like domains show sequence characteristics of Ig
V-like domains (Table 1) although they were previously classified and modeled
as C2 domains (Hibbs et al 1994). The most significant difference between
FcγRIIIA and FcγRIIIB is that FcγRIIIA encodes a protein with a polypeptide
transmembrane region and a cytoplasmic domain of 25 amino acids, whereas
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FcγRIIIB encodes a protein that is anchored to the membrane by a glycophos-
phatidyl inositol linkage (Ravetch & Perussia 1989) (Figure 2). The FcγRIIIA
and FcγRIIIB receptors have different cellular distributions, with FcγRIIIA
found on macrophages, natural killer cells, and mast cells, whereas FcγRIIIB
is expressed mainly on neutrophils (van de Winkel & Anderson 1991, Hulett
& Hogarth 1994). By contrast to the human system, a single murine FcγRIII
isoform expressed on macrophages and natural killer cells consists of two ex-
tracellular Ig domains and a polypeptide membrane linkage (previously called
FcγRIIa; Ravetch et al 1986).
The  chain of murine FcγRIII associates with the γ chain (Kurosaki &
Ravetch 1989), whereas human FcγRIIIA  associates with γ (Hibbs et al
1989) as well as  chains (in natural killer cells) (P Anderson et al 1990, Lanier
et al 1989). The γ and  chains protect the  chain from degradation in the
endoplasmic reticulum, and the absence of associated γ or  chains results in a
reduction in cell surface expression of the transmembrane FcγRIII (Kurosaki
& Ravetch 1989, Ra et al 1989). The in vivo role of FcγRIII in mediating
ADCC was examined by studying γ -deficient mice. Natural killer cells from
γ -deficient mice cannot mediate ADCC because of the absence of cell surface
FcγRIII (Takai et al 1994).
In addition to its role in ADCC, in vitro experiments demonstrated that
FcγRIII functions in endocytosis and phagocytosis (van de Winkel & Anderson
1991, Amigorena et al 1992b, Daeron et al 1994, Nagarajan et al 1995). Murine
FcγRIIIA mediates rapid internalization of antibody-antigen complexes and en-
hances the efficiency of antigen presentation. Tyrosines in the ARAM motif
of the γ subunit are required for signaling the internalization (Amigorena et al
1992b) and phagocytosis of antibody-coated erythrocytes (Daeron et al 1994).
Transfection experiments in Chinese hamster ovary (CHO) cells showed that
FcγRIIIA, when co-expressed with the γ chain, mediates phagocytosis of IgG-
coated erythrocytes (Nagarajan et al 1995). By contrast, CHO cells expressing
FcγRIIIB alone can bind IgG-coated erythrocytes, but not mediate their phago-
cytosis, suggesting that the lipid-linked FcγRIIIB does not deliver a phagocytic
signal in CHO cells (Nagarajan et al 1995). However, it has been suggested that
FcγRIIIB can work synergistically with FcγRII to enhance responses such as
phagocytosis (Edberg et al 1992, Edberg & Kimberly 1994).
FcγRIII-IgG INTERACTION Similar to results described for FcγRI and FcγRII,
the IgG-binding site of FcγRIII is thought to primarily involve the second
Ig domain (the membrane proximal domain) (Hibbs et al 1994). When the
results of mutagenesis and binding studies were mapped onto a model of this
domain as a C2-set domain, the C to C0 loop was identified as the major site
of IgG interaction, with contributions from the B to C and E to F loops (Hibbs
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et al 1994) (underlined in Table 1). The authors concluded that the FcγRIII
interaction site lies on the portion of domain 2 that is furthest from domain 1
because of the positions of two of the three implicated loops (C to C0 and E to
F, at the bottom of a C2 domain; Figure 3). By contrast, mutagenesis studies
implicate the opposite portion of domain 2 of FcγRII in the interaction with IgG
(Hulett & Hogarth 1994) (see above). Further work will be required to resolve
whether the modes of FcγRIII and FcγRII interactions with IgG are different.
The interaction site on IgG for FcγRIII involves the same region of the
IgG molecule as does the binding site for FcγRI and FcγRII, the lower hinge
region just N-terminal to the Cγ 2 domain (Jefferis et al 1990, Morgan et al
1995) (Figure 1b), but regions within the Cγ 3 domain might also be involved
(Gergely & Sarmay 1990).
Recent analytical ultracentrifugation experiments demonstrated that the stoi-
chiometry of the FcγRIII-IgG interaction is 1:1 (Ghirlando et al 1995). A steric
hindrance mechanism is one explanation for the observation that only one re-
ceptor binds per homodimeric Fc region, i.e. the binding of the first receptor
to IgG hinders binding of the second. The location of the FcγR binding site
on the lower hinge, where the two Cγ 2 domains are in close spatial proximity,
is consistent with this idea. The authors use thermodynamic data in support of
a conformational change mechanism to explain the occupancy of only one of
the two available sites on the Fc homodimer, whereby the binding of the first
receptor molecule induces a conformational change that renders the second
binding site on Fc nonfunctional (Ghirlando et al 1995). The exact details of
the interaction of FcγRIII and the other FcγRs with IgG await the appropriate
crystal structures. However, the currently available studies of the interactions
of IgGs with the FcγRs and FcRn, and IgE with FcRI (see below), hint that
these interactions are not as symmetric as might be initially assumed given the
twofold symmetry of the IgGFc fragment in the crystal structure (Deisenhofer
1981) (Figure 1b).
FcRI
FcRI is a high-affinity receptor, binding to monomeric IgE with an equi-
librium constant of  1  1010 M−1 (Beavil et al 1993). IgE is present in
very low concentrations in human serum (5–300 ng/ml), and the high-affinity
binding permits a dramatic amplification of IgE-antigen interactions (Sutton
& Gould 1993). Upon being cross-linked by the binding of IgE to a multiva-
lent antigen, FcRI mediates a variety of allergic and inflammatory responses
(Metzger 1991, Sutton & Gould 1993). Mast cells in tissues and basophils
in blood express FcRI and are thought to be the cells principally responsible
for an allergic response. Allergic reactions commonly begin with the produc-
tion of IgE in response to pollen, cat dander, or other environmental antigens.
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Receptor cross-linking triggered by the binding of these multivalent allergens
to cell surface IgE-FcRI complexes results in the degranulation of cells and
the release of stored mediators of inflammation, including histamine, serotonin,
and leukotrienes (Metzger 1991, Sutton & Gould 1993). Recent in vivo studies
confirm the importance of FcRI in the allergic response, in that the disruption
of the FcRI  chain gene in mice resulted in a failure of the mice to mount
anaphylactic responses (Dombrowicz et al 1994). The more beneficial role of
FcRI is thought to involve the immune defense against parasites (Janeway &
Travers 1994). Mast cell release of inflammatory mediators caused by cross-
linking of FcRI through IgE binding of multivalent antigen induces smooth
muscle contractions, with the result that mast cell degranulation results in pro-
tective responses such as vomiting, coughing, and sneezing that can help in
expelling an invading organism (Janeway & Travers 1994).
FcRI STRUCTURE FcRI occurs on cell surfaces as a complex of four polypep-
tide chains: a ligand binding or  chain, a  chain, and a disulfide-linked γ
chain homodimer (Blank et al 1989) (Figure 2). The  chain consists of two
extracellular Ig-like domains, a single transmembrane sequence, and a cyto-
plasmic domain of about 20 to 31 amino acids (Kinet et al 1987, Metzger
1991). Although the Ig-like domains of FcRI were classified and modeled as
C2-type domains (Sutton & Gould 1993; reviewed in Hulett & Hogarth 1994),
we believe they share more similarity with V-like domains (Table 1). The 
chain is predicted to contain four membrane-spanning domains, with the amino
and carboxy termini being located on the cytoplasmic side (Kinet et al 1988).
FcRI-IgE INTERACTION Chimeric FcRI-FcγRIIIA and chimeric rodent-
human FcRI were used to demonstrate that substitution of the second FcRI 
chain extracellular domain (the membrane proximal domain) resulted in a loss
of IgE binding (Mallamaci et al 1993, Robertson 1993). Further mutagenesis
studies identified four regions in domain 2 as being important for interaction
with IgE: residues 93–104, 111–125 and 129–137, and 154–161 (Mallamaci
et al 1993, Hulett & Hogarth 1994) (underlined in Table 1). When the results
of these studies were mapped onto a C2 set-based model of domain 2, the IgE
interaction site was situated primarily in the portion of domain 2 near the in-
terface with domain 1: the F to G, C0 to E, and B to C loops, and contributions
from the B and C strands (Table 1) (Sutton & Gould 1993, Hulett & Hogarth
1994). Although the main site of IgE interaction involves the second FcRI
domain, the observation that a mutant FcRI  chain containing only the sec-
ond extracellular domain binds with lower affinity than the two-domain protein
suggests that regions in the first domain are required for high-affinity binding
(Robertson 1993).
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The binding site on IgE for FcRI has been mapped to the interface between
the C2 and C3 domains (Helm et al 1988, Weetall et al 1990, Nissim et al
1993), primarily involving residues of the C3 domain, based upon the studies
of the binding of chimeric rodent-human IgE molecules to rodent and human
FcRI (Nissim et al 1993), and numerous other studies (Beavil et al 1993, Hulett
& Hogarth 1994). Because the IgE heavy chain contains an extra domain, C2,
in the region corresponding to the IgG hinge (Figure 1a), the C2-C3 interface
may be analogous to the IgG hinge-Cγ 2 interface identified as the binding site
of the FcγRs.
Fluorescence resonance energy transfer measurements demonstrated that IgE
in solution is bent, such that the average end-to-end distance between the Fab
and Fc segments is only 75 A˚ rather than the 180 A˚ predicted for a planar
Y-shaped IgE structure (Baird et al 1993). Fluorescence energy transfer studies
were also used to compare the conformation of IgE alone and IgE when bound
to FcRI. The receptor-bound IgE was also bent, with an average end-to-end
distance between the Fab and Fc segments of about 71 A˚ (Baird et al 1993). The
bending of IgE should result in an asymmetric structure of the homodimeric IgE
Fc region, such that only one of the two polypeptide chains of the Fc provides
a binding site for FcRI. Indeed, the observed stoichiometry of the IgE-FcRI
interaction is 1:1 (Robertson 1993), consistent with the idea that the bent region
of IgE presents one concave and one convex surface, with the receptor site
occluded on the concave surface (Baird et al 1993, Sutton & Gould 1993).
Further analysis of the spectroscopic studies suggests that the Fc region of
FcRI-bound IgE lies parallel to the membrane, based on measurements of the
distances between the fluorophores on IgE and a fluorophore in the membrane
(Baird et al 1993). This information implies a lying-down orientation for cell
surface FcRI (Figure 2), reminiscent of the lying-down orientation proposed
for the FcRn dimer (Burmeister et al 1994a,b) (Figure 5a,b). Because of the
similarities in the predicted interfaces of the FcγR-IgG and the FcRI-IgE
complexes, and the sequence similarities between the FcγRs and FcRI, a
lying-down orientation on the membrane may be a common feature of many
FcRs.
CONCLUSIONS
Most FcRs that are members of the Ig superfamily have related structures con-
sisting of two or more Ig-like domains arranged in tandem, a domain orga-
nization shared by many cell adhesion molecules. FcRn, a heterodimer with
an overall structural similarity to class I MHC molecules, is structurally dis-
tinct from the other Ig superfamily FcRs reviewed here (pIgR, the FcγRs, and
FcRI). There are several common elements in the interactions of the adhesion
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molecule-like FcRs with Ig, which usually are not features of the interaction of
FcRn with IgG.
First, the binding site on IgG for all the FcγRs involves the hinge and the
hinge-proximal portion of the Cγ 2 domain. The binding site for FcRI is at
the C2-C3 interface, an analogous location on the IgE molecule. By con-
trast, FcRn binds to IgG at a different site, the interface between the Cγ 2 and
Cγ 3 domains, where Fc histidine residues mediate part of the pH-dependent
interaction between FcRn and IgG.
A second common feature of the FcγRs and FcRI is a 1:1 receptor-Ig
stoichiometry in the case of FcγRI, FcγRIII, and FcRI, which suggests asym-
metry in the Fc regions of receptor-bound Igs, such that one receptor binding
site on the Fc homodimer is inaccessible. Strong evidence suggests that the
IgE Fc region is bent, which may contribute to the inaccessibility of the second
receptor binding site on IgE molecules. Biophysical studies also suggest that
the Fc region of IgG is bent and can therefore bind asymmetrically to the FcγR
receptors, which may explain the observation that only one of the two sites
at the hinge-proximal end of the Cγ 2 domain is available for interaction with
FcγRI and FcγRIII. By contrast, both sites at the Cγ 2-Cγ 3 domain interface
of IgG are accessible for interaction with FcRn in the crystals of FcRn bound
to Fc; thus bending of IgG does not occlude either of the sites in this region of
Fc at the high protein concentrations found in the crystals.
Another common feature of some of the adhesion molecule-like FcRs is
the use of the membrane-proximal domain (domain 2 of FcγRII, FcγRIII,
and FcRI; domain 3 of FcγRI) as the primary Ig-binding site, with possible
contributions from the membrane distal domain(s). By contrast, pIgR binds
to IgA primarily with its N-terminal domain, which is more typical of the
interactions of adhesion molecules such as CD2, CD4, and ICAM-1 with their
ligands. Because FcRn is so different structurally from the other FcRs, its
interactions with IgG bear no resemblance to the Ig interactions of either pIgR
or the other FcRs. The IgG-binding site is on the edge of the 1 and 2
domain platform, with contributions from the 2m subunit. This mode of
interaction also does not resemble the ways that MHC proteins interact with
any other molecules, including peptides, T-cell receptors and coreceptors, or
superantigens.
Finally, in what appears to be the only common feature of Ig interaction
between FcRn and the other Ig superfamily FcRs, a lying-down orientation was
proposed for cell surface FcRI and FcRn. The orientations of the remaining
receptors on the membrane are unknown, but the similarities in sequence and
domain organization between FcRI and the FcγRs suggests this orientation
may be relevant for the other receptors as well.
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A more complete understanding of FcR-Ig interaction awaits high-resolution
crystal structures of the adhesion molecule-like receptors in complex with their
Fc ligands. In the absence of these structures, models of the FcγR and FcRI
domains were constructed using the available Ig-like domain structures from
cell adhesion molecules. Our analysis of the sequences of the FcγR and FcRI
domains suggests that they have many features in common with V-like domains,
although they had been classified as members of the C2 set. V-like and C2
domains differ primarily in the region between the C and E strands, which
includes a region mapped as an Ig interaction site for some of these receptors.
Further studies are required to resolve this issue, which promise to be of great
interest owing to the recent advances in the understanding of the physiological
functions of these receptors.
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